Skip to main content
Fig. 1 | Respiratory Research

Fig. 1

From: Effect of active vitamin D3 on VEGF-induced ADAM33 expression and proliferation in human airway smooth muscle cells: implications for asthma treatment

Fig. 1

1,25(OH)2D3 inhibits VEGF-induced ADAM33 expression at both mRNA and protein level. ASM cells were incubated with various doses of 1,25(OH)2D3 for 9 h before treatment or not with 50 ng/ml of VEGF for 30 min, and then real-time PCR performed (a). ASM cells were incubated at indicated times of 100 nM of 1,25(OH)2D3, and then real-time PCR performed (b). The values are normalized relative to the GAPDH standard. ASM cells were incubated with various doses of 1,25(OH)2D3 for 24 h before treatment or not with 50 ng/ml of VEGF for 30 min, and then western blotting analysis for ADAM33 was performed (c). ASM cells were incubated at indicated times of 100 nM of 1,25(OH)2D3 before treatment or not with 50 ng/ml of VEGF for 30 min, and then western blotting analysis for ADAM33 was performed (d). β-actin was used as a loading control. All data are representative of three independent experiments. Values represent the means  ±  SEM. * P  <  0.05 vs. control, # P  <  0.05, ## P  <  0.005 vs. VEGF alone

Back to article page